US FDA grants Hemispherx more time on rejected Ampligen NDA
This article was originally published in Scrip
Executive Summary
Shares of Hemispherx Biopharma gained 14.3%, or 3 cents, on 11 January after the company revealed that the US FDA granted more time for the firm to respond to a November 2009 complete response letter for its application to market its chronic fatigue syndrome (CFS) therapy Ampligen.